Ad hoc announcement pursuant to Art. 53 LR
1
Relief Reports that its U.S. Collaboration Partner has announced that it has
Submitted an Application to the FDA seeking Emergency Use Authorization for
Aviptadil to Treat Patients at Immediate Risk of Death from COVID-19 Despite
Treatment with Remdesivir and Other Approved Therapies
Geneva, Switzerland, January 6, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY)
(Relief), a biopharmaceutical company seeking to provide patients therapeutic relief from serious
diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc.
(Nasdaq: NRXP) (NRx), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx")
has announced that it has submitted an application to the FDA seeking emergency use authorization
("EUA") for the use of aviptadil to treat patients with critical COVID-19 who are at immediate risk of death
from respiratory failure despite treatment with approved therapy including Remdesivir and who are
ineligible for enrollment into the ACTIV-3b NIH-sponsored trial. The related NRx press release can be
accessed through the following link.
Relief also updated the market on recent activities in its pending lawsuit against NeuroRx and NeuroRx's
CEO, Jonathan Javitt (collectively, the "Defendants"), relating to the parties' collaboration agreement with
respect to the development and commercialization of aviptadil. Relief reported that the Defendants have
filed two motions with the Court: (i) a motion to dismiss seeking the dismissal of Jonathan Javitt from the
case for lack of personal jurisdiction, or, in the alternative, on the merits, and (ii) a motion to strike certain
statements made in Relief's complaint. Relief has begun its review of the defendants' filings and will
respond at a future time in an appropriate filing with the Court. While there can be no assurance, Relief
remains confident in the statements made in its complaint and in the validity of its claims against NeuroRx
and Jonathan Javitt. Relief also reported that its previously announced mediation with the Defendants
seeking to amicably resolve the litigation is currently scheduled for late February 2022.
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing
and use in human patients or a strong scientific rationale. Reliefs lead drug candidate, RLF-100
(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S.
for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,
in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the
worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate
release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle
Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR
Ad hoc announcement pursuant to Art. 53 LR
2
Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed
and development-stage programs.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in
the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit
www.relieftherapeutics.com.
Follow us on LinkedIn.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements
concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks,
uncertainties and other factors, including (i) whether NeuroRx's recently submitted application to the FDA
seeking for EUA for aviptadil to treat patients with critical COVID-19 who are at immediate risk of death
from respiratory failure despite treatment with approved therapy including Remdesivir and who are
ineligible for enrollment into the ACTIV-3b NIH-sponsored trial will be approved, (ii) whether RELIEF
THERAPEUTICS Holding SA will be successful in its lawsuit against NRx's subsidiary, NeuroRx, and
NeuroRx's CEO, Jonathan Javitt, (iii) whether the mediation will be successful, (iv) whether aviptadil will
ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with
COVID-19 or any other disease, and (v) those risks discussed in RELIEF THERAPEUTICS Holding SA's press
releases and filings with the SIX, which could cause the actual results, financial condition, performance or
achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking statements. RELIEF
THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new information, future events or
otherwise.
Zurück
